ADOPT: evidence for change?

A randomised controlled trial published in a peer‐reviewed journal is considered to be the ‘gold standard’ of information about the effectiveness of a treatment; however, critical appraisal of trials is required in order to judge the value and implications of the results. Here, the author presents an appraisal of the ADOPT study, which compared the efficacy of rosiglitazone, metformin and glibenclamide in the treatment of type 2 diabetes.

Glycaemic durability of rosiglitazone, metformin, or glyburide monotherapy (the ADOPT study). N Engl J Med 2006;355:2427–43. Copyright © 2007 Wiley Interface Ltd